Workflow
Avidity Biosciences, Inc. (RNA) Redefining the Treatment of Duchenne Muscular

Group 1 - Avidity Biosciences is presenting the first functional data from the EXPLORE44 open-label extension study of Del-zota, targeting boys and young men living with Duchenne Muscular Dystrophy (DMD) [1] - Katja Lange serves as the Chief Business Officer at Avidity Biosciences and is leading the presentation [1] - The presentation is part of a broader effort to share advancements in treatment options for DMD [1] Group 2 - The presentation includes forward-looking statements that involve risks and uncertainties, which may lead to actual results differing from those anticipated [2] - Stakeholders are advised to refer to detailed cautionary language and risk factors in recent SEC filings [2]